Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1967
Name leiomyosarcoma
Definition A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer muscle cancer smooth muscle cancer leiomyosarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 positive PD173074 leiomyosarcoma decreased response detail...
FGFR1 positive Fexagratinib leiomyosarcoma decreased response detail...
FGFR1 positive Infigratinib leiomyosarcoma decreased response detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed USA 0
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed USA 0
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Completed USA 0
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting ITA | FRA | ESP 0
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Completed USA 0
NCT02303262 Phase II Gemcitabine + Mocetinostat A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed USA 0
NCT02406781 Phase II Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) Unknown status FRA 0
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Completed USA 0
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Terminated USA 0
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed USA 0
NCT02923778 Phase II Talimogene laherparepvec Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Active, not recruiting USA | CAN 0
NCT02987959 Phase II Sapanisertib Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Terminated USA 0
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Completed USA 0
NCT03016819 Phase III Anlotinib Dacarbazine A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS) Active, not recruiting USA | ITA | GBR | ESP 1
NCT03074318 Phase Ib/II Avelumab + Trabectedin Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT03114527 Phase II Everolimus + Ribociclib Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Active, not recruiting USA 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Completed ITA | GBR | ESP 0
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03420014 Phase II Doxorubicin + Onfekafusp alfa Doxorubicin Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (FIBROSARC US) Recruiting USA 0
NCT03437070 Phase I Doxorubicin + Olaratumab + Trabectedin Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma Withdrawn 0
NCT03474094 Phase II Atezolizumab Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) Recruiting GBR | FRA 0
NCT03548428 Phase II Atezolizumab Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) Recruiting FRA 0
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Terminated USA 0
NCT03718091 Phase II Berzosertib M6620 (VX-970) in Selected Solid Tumors Completed USA 0
NCT03719430 Phase II Doxorubicin + Olaratumab + Sotigalimab APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Active, not recruiting USA 0
NCT03761095 Phase I Dacarbazine + Unesbulin A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Completed USA 0
NCT03793361 Phase II Regorafenib Phase II Study of Regorafenib as Maintenance Therapy Active, not recruiting FRA 0
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Active, not recruiting CAN 0
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT03899805 Phase II Eribulin + Pembrolizumab A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Active, not recruiting USA 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Active, not recruiting USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS 2
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting USA 0
NCT04076579 Phase II Olaparib + Trabectedin Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Active, not recruiting USA 0
NCT04200443 Phase II Cabozantinib + Temozolomide Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04216953 Phase Ib/II Atezolizumab + Cobimetinib MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) Active, not recruiting FRA 0
NCT04242238 Phase I Avelumab + Vimseltinib Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Active, not recruiting USA 0
NCT04383119 Phase II Gemcitabine Trabectedin Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (ISG-ARTICLE) Recruiting ITA 0
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04535271 Phase II Dacarbazine + Gemcitabine + Trabectedin Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma Recruiting USA 0
NCT04595994 Phase I Selinexor Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Recruiting ESP 0
NCT04624178 Phase II Nivolumab + Rucaparib A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Active, not recruiting USA 0
NCT04784247 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04807816 Phase II Berzosertib + Gemcitabine Gemcitabine Targeting ATR in Soft-tissue Sarcomas (TARSARC) Recruiting FRA 0
NCT04811196 Phase I Selinexor A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients Active, not recruiting CAN 0
NCT04874311 Phase II Bintrafusp alfa + Doxorubicin Doxorubicin Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) Recruiting FRA 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT04996004 Phase Ib/II Doxorubicin + TTI-621 A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma Terminated USA 0
NCT05043649 Phase I Camsirubicin + Pegfilgrastim Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Terminated USA 0
NCT05080790 Phase II Aldesleukin + Dinutuximab + Zoledronic acid Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) Active, not recruiting DEU 0
NCT05116683 Phase II ATX101 ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101) Terminated USA 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05174455 Phase II Niraparib Niraparib for the Treatment of Leiomyosarcoma Withdrawn 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0
NCT05597917 Phase III Trabectedin Trabectedin + tTF-NGR tTF-NGR Randomized Study - STS (TRABTRAP) Recruiting DEU | AUT 0
NCT05711615 Phase I Pegylated liposomal doxorubicin + Peposertib Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Recruiting USA 0
NCT05712694 Phase III ADI-PEG 20 + Docetaxel + Gemcitabine Docetaxel + Gemcitabine Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) Recruiting USA | CAN 1
NCT05809830 Phase Ib/II Doxorubicin Doxorubicin + LB-100 Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) Recruiting ESP 0
NCT05821231 Phase I MEDI5752 Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT) Recruiting FRA 0
NCT05836571 Phase II Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Recruiting USA | CAN 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05879185 Phase II Izuralimab A Study of XmAb23104 in People With Sarcoma Terminated USA 0
NCT06088290 Phase II Doxorubicin Doxorubicin + Lurbinectedin Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma Recruiting USA | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT 0
NCT06114004 Phase II Gemcitabine + Selinexor Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) (SeliSarc) Recruiting ESP 0
NCT06263231 Phase III Eribulin Trabectedin Pazopanib INT230-6 A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3) Recruiting USA 0
NCT06308419 Phase I Gemcitabine + Nab-rapamycin A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions Recruiting USA 0
NCT06528769 Phase II Cemiplimab + Tretinoin A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma Not yet recruiting USA 0
NCT06571734 Phase II XL092 XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma Recruiting USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0